Abstract Search

ea0060oc2 | (1) | UKINETS2018

Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study

Prasad Vikas , Srirajaskanthan Raj , Toumpanakis Christos , Grana Chiara Maria , Baldari Sergio , Shah Tahir , Lamarca Angela , Courbon Frederic , Scheidhauer Klemens , Baudin Eric , Thanh Xuan Mai Truong , Houchard Aude , Bodei Lisa

Background: PRRT, licensed for gastroenteropancreatic (GEP) NETs, has been used with somatostatin analogues such as lanreotide autogel (LAN). PRELUDE is the first international, multicentre retrospective study, with central radiology reading, to describe use of LAN with PRRT (LAN-PRRT) in advanced NETs.Methods: PRELUDE (NCT02788578) was an international, retrospective, non-comparative analysis of medical records of patients receiving LAN with 177Lu-DOTAT...

0 shares

Endocrine Abstracts

Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study

BiosciAbstracts